Brandon Folkes
Stock Analyst at Rodman & Renshaw
(1.86)
# 1,599
Out of 4,667 analysts
47
Total ratings
26.09%
Success rate
-2.52%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMTI Rockwell Medical | Initiates: Buy | $5 | $2.33 | +114.59% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $4.31 | +178.75% | 1 | Nov 14, 2024 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $9 | $3.60 | +150.00% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $6.03 | +49.25% | 2 | Nov 14, 2024 | |
| ADIL Adial Pharmaceuticals | Initiates: Buy | $8 | $1.02 | +684.31% | 1 | Nov 14, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $16 | $8.88 | +80.18% | 6 | Sep 13, 2024 | |
| CRMD CorMedix | Initiates: Buy | $13 | $10.74 | +21.04% | 1 | Aug 26, 2024 | |
| MIST Milestone Pharmaceuticals | Initiates: Buy | $9 | $1.86 | +383.87% | 1 | Aug 22, 2024 | |
| MNKD MannKind | Initiates: Buy | $8 | $6.88 | +16.28% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $2.77 | +152.71% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.12 | +525.00% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.05 | +387.80% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.56 | +2,202.52% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $37.28 | +58.26% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $119.24 | +50.96% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.63 | +3,418.31% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.23 | +72.08% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $27.91 | +14.65% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $6.40 | +343,650.00% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $30.00 | -26.67% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $720 | $3.49 | +20,530.37% | 1 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $55.10 | -27.40% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $27 → $21 | $0.37 | +5,622.07% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $46.83 | +6.77% | 1 | Jul 12, 2018 |
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $2.33
Upside: +114.59%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $4.31
Upside: +178.75%
Eupraxia Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.60
Upside: +150.00%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $6.03
Upside: +49.25%
Adial Pharmaceuticals
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $1.02
Upside: +684.31%
Emergent BioSolutions
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.88
Upside: +80.18%
CorMedix
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $10.74
Upside: +21.04%
Milestone Pharmaceuticals
Aug 22, 2024
Initiates: Buy
Price Target: $9
Current: $1.86
Upside: +383.87%
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $6.88
Upside: +16.28%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $2.77
Upside: +152.71%
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $1.12
Upside: +525.00%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $2.05
Upside: +387.80%
Jun 13, 2024
Initiates: Buy
Price Target: $13
Current: $0.56
Upside: +2,202.52%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $37.28
Upside: +58.26%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $119.24
Upside: +50.96%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.63
Upside: +3,418.31%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $5.23
Upside: +72.08%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $27.91
Upside: +14.65%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $6.40
Upside: +343,650.00%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $30.00
Upside: -26.67%
Jul 30, 2021
Initiates: Overweight
Price Target: $720
Current: $3.49
Upside: +20,530.37%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $55.10
Upside: -27.40%
Mar 5, 2020
Reiterates: Overweight
Price Target: $27 → $21
Current: $0.37
Upside: +5,622.07%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $46.83
Upside: +6.77%